WO2022080986A1 - Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 - Google Patents
Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 Download PDFInfo
- Publication number
- WO2022080986A1 WO2022080986A1 PCT/KR2021/014462 KR2021014462W WO2022080986A1 WO 2022080986 A1 WO2022080986 A1 WO 2022080986A1 KR 2021014462 W KR2021014462 W KR 2021014462W WO 2022080986 A1 WO2022080986 A1 WO 2022080986A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- conjugate
- domain
- group
- glp
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 229940125542 dual agonist Drugs 0.000 title abstract description 62
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract description 80
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 32
- 239000012453 solvate Substances 0.000 claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 108
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims description 79
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims description 79
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 76
- 230000000694 effects Effects 0.000 claims description 57
- 150000001413 amino acids Chemical group 0.000 claims description 56
- 108060003951 Immunoglobulin Proteins 0.000 claims description 45
- 102000018358 immunoglobulin Human genes 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 45
- 229920000642 polymer Polymers 0.000 claims description 28
- 239000000560 biocompatible material Substances 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 23
- 239000002202 Polyethylene glycol Substances 0.000 claims description 21
- 229920001223 polyethylene glycol Polymers 0.000 claims description 21
- 238000009739 binding Methods 0.000 claims description 20
- 108091033319 polynucleotide Proteins 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000000539 dimer Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 6
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 102000009027 Albumins Human genes 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 102000004338 Transferrin Human genes 0.000 claims description 4
- 108090000901 Transferrin Proteins 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
- 229920002988 biodegradable polymer Polymers 0.000 claims description 4
- 239000004621 biodegradable polymer Substances 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 239000012581 transferrin Substances 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 108010014258 Elastin Proteins 0.000 claims description 3
- 102000016942 Elastin Human genes 0.000 claims description 3
- 229920002549 elastin Polymers 0.000 claims description 3
- 229920006158 high molecular weight polymer Polymers 0.000 claims description 3
- 102000016359 Fibronectins Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 210000002808 connective tissue Anatomy 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 75
- 229940024606 amino acid Drugs 0.000 description 52
- 235000001014 amino acid Nutrition 0.000 description 52
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 45
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 44
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 44
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 42
- -1 aromatic amino acids Chemical class 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 35
- 239000008280 blood Substances 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 34
- 125000003275 alpha amino acid group Chemical group 0.000 description 33
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 28
- 235000004279 alanine Nutrition 0.000 description 28
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 27
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 26
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 25
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 24
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 24
- 239000004472 Lysine Substances 0.000 description 24
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 24
- 235000004554 glutamine Nutrition 0.000 description 24
- 235000018977 lysine Nutrition 0.000 description 24
- 235000000346 sugar Nutrition 0.000 description 24
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 23
- 230000009977 dual effect Effects 0.000 description 23
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 21
- 125000005647 linker group Chemical group 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 19
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 19
- 238000007363 ring formation reaction Methods 0.000 description 19
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 17
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 17
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 17
- 125000006239 protecting group Chemical group 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 16
- 229960000310 isoleucine Drugs 0.000 description 16
- 239000004475 Arginine Substances 0.000 description 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 15
- 235000009697 arginine Nutrition 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 206010022489 Insulin Resistance Diseases 0.000 description 14
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 235000003704 aspartic acid Nutrition 0.000 description 14
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 14
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 14
- 235000014304 histidine Nutrition 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000004471 Glycine Substances 0.000 description 13
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 13
- 239000004220 glutamic acid Substances 0.000 description 13
- 235000013922 glutamic acid Nutrition 0.000 description 13
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 13
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 12
- 235000018417 cysteine Nutrition 0.000 description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 235000004400 serine Nutrition 0.000 description 12
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 11
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 235000009582 asparagine Nutrition 0.000 description 11
- 229960001230 asparagine Drugs 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 10
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 9
- 208000001145 Metabolic Syndrome Diseases 0.000 description 9
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 125000001151 peptidyl group Chemical group 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 208000002249 Diabetes Complications Diseases 0.000 description 8
- 206010012655 Diabetic complications Diseases 0.000 description 8
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 108091005995 glycated hemoglobin Proteins 0.000 description 8
- 102000050325 human granulocyte inhibitory Human genes 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000001603 reducing effect Effects 0.000 description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000009833 condensation Methods 0.000 description 7
- 230000005494 condensation Effects 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- PRJKNHOMHKJCEJ-UHFFFAOYSA-N imidazol-4-ylacetic acid Chemical group OC(=O)CC1=CN=CN1 PRJKNHOMHKJCEJ-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 235000008521 threonine Nutrition 0.000 description 6
- 239000004474 valine Substances 0.000 description 6
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 125000003172 aldehyde group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000002585 base Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000010306 acid treatment Methods 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 239000008004 cell lysis buffer Substances 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- ZUSSTQCWRDLYJA-UMRXKNAASA-N n-hydroxy-5-norbornene-2,3-dicarboxylic acid imide Chemical compound C([C@@H]1C=C2)[C@@H]2[C@@H]2[C@H]1C(=O)N(O)C2=O ZUSSTQCWRDLYJA-UMRXKNAASA-N 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical class CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 2
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- RFBKULCUBJAQFT-BIIVOSGPSA-N Ser-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CO)N)C(=O)O RFBKULCUBJAQFT-BIIVOSGPSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- SMTOKHQOVJRXLK-UHFFFAOYSA-N butane-1,4-dithiol Chemical compound SCCCCS SMTOKHQOVJRXLK-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000003951 lactams Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- DKXIKPOYTWCGIE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-methylbutanoate Chemical compound CCC(C)C(=O)ON1C(=O)CCC1=O DKXIKPOYTWCGIE-UHFFFAOYSA-N 0.000 description 1
- FHNMAOLQZHUPIJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-methylpropanoate Chemical compound CC(C)C(=O)ON1C(=O)CCC1=O FHNMAOLQZHUPIJ-UHFFFAOYSA-N 0.000 description 1
- DYMYLBQTHCJHOQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) butanoate Chemical compound CCCC(=O)ON1C(=O)CCC1=O DYMYLBQTHCJHOQ-UHFFFAOYSA-N 0.000 description 1
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 1
- DRLIANXPAARUMI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) pentanoate Chemical compound CCCCC(=O)ON1C(=O)CCC1=O DRLIANXPAARUMI-UHFFFAOYSA-N 0.000 description 1
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
- PQMFVUNERGGBPG-UHFFFAOYSA-N (6-bromopyridin-2-yl)hydrazine Chemical compound NNC1=CC=CC(Br)=N1 PQMFVUNERGGBPG-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- LHJGJYXLEPZJPM-UHFFFAOYSA-N 2,4,5-trichlorophenol Chemical compound OC1=CC(Cl)=C(Cl)C=C1Cl LHJGJYXLEPZJPM-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- GGDYAKVUZMZKRV-UHFFFAOYSA-N 2-fluoroethanol Chemical compound OCCF GGDYAKVUZMZKRV-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 1
- QGHDLJAZIIFENW-UHFFFAOYSA-N 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxy-3-prop-2-enylphenyl)propan-2-yl]-2-prop-2-enylphenol Chemical group C1=C(CC=C)C(O)=CC=C1C(C(F)(F)F)(C(F)(F)F)C1=CC=C(O)C(CC=C)=C1 QGHDLJAZIIFENW-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000008719 DCA Vantage Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000851054 Homo sapiens Elastin Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- KPFBUSLHFFWMAI-HYRPPVSQSA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-6-formyl-3-methoxy-10,13-dimethyl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C[C@@H]2[C@](CCC(OC)=C3)(C)C3=C(C=O)C[C@H]2[C@@H]2CC[C@](OC(C)=O)(C(C)=O)[C@]21C KPFBUSLHFFWMAI-HYRPPVSQSA-N 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003006 anti-agglomeration agent Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- RXUBZLMIGSAPEJ-UHFFFAOYSA-N benzyl n-aminocarbamate Chemical compound NNC(=O)OCC1=CC=CC=C1 RXUBZLMIGSAPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- DZAUWHJDUNRCTF-UHFFFAOYSA-N dihydrocaffeic acid Natural products OC(=O)CCC1=CC=C(O)C(O)=C1 DZAUWHJDUNRCTF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 1
- 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005934 tert-pentyloxycarbonyl group Chemical group 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- GLP-1 / GIP dual agonist a long-acting conjugate thereof, and a pharmaceutical composition for preventing or treating diabetes comprising the same.
- GLP-1 Glucagon-like peptide-1
- GLP-1 Glucagon-like peptide-1
- GLP-1 is an incretin hormone secreted from the small intestine upon stimulation by food intake. It helps to lower the concentration. In addition, it acts as a satiety factor, slowing the digestion of the stomach, and delaying the passage time of the digested food, thereby reducing food intake.
- food intake suppression and weight loss effect when administered to rats were confirmed, and these effects were confirmed to be the same in both normal and obese states, showing potential as a treatment for obesity.
- GIP glycose-dependent insulinotropic polypeptide
- GIP is one of the representative incretin hormones secreted from the gastrointestinal tract and is a neurohormone, similar to GLP-1, secreted upon stimulation by food intake.
- GIP is a hormone composed of 42 amino acids secreted from the K cells of the small intestine and has a function in maintaining the homeostasis of blood sugar by regulating the secretion of insulin or glucagon from the pancreas depending on the blood glucose concentration, as well as the central nervous system like GLP-1. and the function of suppressing diet through the vagus nerve have also been reported.
- GLP-1 In the case of GLP-1, it has been prescribed to diabetic and obese patients for more than 10 years as a treatment for diabetes as well as obesity through the effect of lowering blood sugar through glucose-dependent insulin secretion and weight loss through suppression of diet. The development of several improved new drugs is also being actively carried out. However, since GLP-1 drugs alone do not reduce the expected effect of HbA1c by more than 2%, diabetic patients with glycated hemoglobin levels exceeding 9% may need the combination of insulin-based drugs. In fact, a combination of GLP-1 and insulin has been approved and used, but it is not free from the risk of hypoglycemia as much as insulin is used. For this reason, GIP, which can control blood sugar and has relatively no risk of hypoglycemia, is emerging as a new partner for GLP-1 drugs.
- a novel GLP-1/GIP dual agonist is provided.
- It provides a vector comprising the polynucleotide.
- It provides a host cell comprising the polynucleotide or vector.
- conjugate in which the GLP-1/GIP dual agonist and a biocompatible material that increases the half-life in vivo are combined.
- compositions for preventing or treating diabetes comprising the GLP-1/GIP dual agonist, a pharmaceutically acceptable salt thereof, a solvate thereof, or the conjugate.
- GLP-1/GIP dual agonist a pharmaceutically acceptable salt thereof, a solvate thereof, or the conjugate for use in the manufacture of a medicament for the prevention or treatment of diabetes.
- amino acids referred to by abbreviation herein are described according to the IUPAC-IUB nomenclature.
- One aspect provides a GLP-1/GIP dual agonist.
- GLP-1 Glucagon-like peptide-1
- GIP glucose-dependent insulinotropic polypeptide or gastric inhibitory polypeptide
- GLP-1/GIP dual agonist (GLP-1/GIP dual agonist) is “GLP-1/GIP receptor dual agonist”, “GLP-1 receptor and GIP receptor dual agonist”, “GLP-1R/GIPR dual agonist” It may be used interchangeably with “agonist”, “dual agonist”, or “peptide having activity on the GLP-1 receptor and on the GIP receptor”.
- the GLP-1/GIP dual agonist may be a peptide having activity on at least one of a GLP-1 receptor and a GIP receptor, specifically, a peptide having activity on a GLP-1 receptor and a GIP receptor.
- the “peptide having activity on the GLP-1 receptor and the GIP receptor” has a significant level of activity on the GLP-1 receptor and the GIP receptor, and specifically, the in vitro activity on the GLP-1 receptor and the GIP receptor About 0.1% or more, 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 6% or more, 7% or more, 8 % or more, 9% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more, 100% or more 500%, or 100% to 200%.
- Example 2 of the present specification For a method of measuring the in vitro activity of the peptide having activity on the GLP-1 receptor and the GIP receptor, see Example 2 of the present specification, but is not particularly limited thereto, and any method known in the art may be used as appropriate. In vitro activity can be measured.
- the GLP-1/GIP dual agonist may exhibit balanced GLP-1 and GIP activity.
- Balanced activity against GLP-1 and GIP means that the affinity of the peptide for the GLP-1 receptor and the GIP receptor in an in vitro binding assay is close to 1:1, specifically a molar ratio of 1:100 to 100:1; More specifically, it refers to a molar ratio of 1:10 to 10:1, and even more specifically, a molar ratio of 1:2 to 2:1.
- “About” is a range inclusive of ⁇ 0.5, ⁇ 0.4, ⁇ 0.3, ⁇ 0.2, ⁇ 0.1, etc., including, but not limited to, all numerical values in a range equal to or similar to the numerical value following the term “about”. .
- the GLP-1/GIP dual agonist is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 in a native or unmutated protein (eg, GLP-1 or GIP).
- Conservative substitutions may be made in one or more amino acids, but the present invention is not limited thereto.
- Constant substitution means substituting an amino acid for another amino acid having similar structural and/or chemical properties.
- the dual agent may have, for example, one or more conservative substitutions while still retaining the biological activity of the native or unmutated GLP-1 or GIP protein.
- Such amino acid substitutions may generally occur based on similarity in the polarity, charge, solubility, hydrophobicity, hydrophilicity and/or amphipathic nature of the residues.
- positively charged (basic) amino acids include arginine, lysine, and histidine
- negatively charged (acidic) amino acids include glutamic acid and aspartic acid
- aromatic amino acids include phenylalanine, tryptophan and tyrosine
- Hydrophobic amino acids include alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine and tryptophan.
- amino acids can be classified into amino acids with electrically charged side chains and amino acids with uncharged side chains.
- Amino acids having a charged side chain include aspartic acid, glutamic acid, lysine, arginine, and histidine, and amino acids having an uncharged side chain can be classified as nonpolar amino acids or polar amino acids.
- the non-polar amino acids are glycine, alanine, valine, leucine, and isoleucine. methionine, proline; Polar amino acids may include serine, threonine, cysteine, asparagine, glutamine. Conservative substitutions with amino acids having similar properties as described above can be expected to exhibit the same or similar activity.
- the GLP-1/GIP dual agonist may be non-naturally occurring.
- the GLP-1/GIP dual agonist may be an isolated peptide.
- the GLP-1/GIP dual agonist is a peptide comprising an amino acid sequence represented by the following general formula 1:
- R1 is 4-imidazoleacetic acid (CA) or absent,
- Xaa1 is tyrosine (Tyr, Y), histidine (His, H), 3-(4-hydroxyphenyl)propanoic acid (3-(4-hydroxyphenyl)propanoic acid, HP), or 2-(4-hydroxyphenyl) acetic acid (2-(4-hydroxyphenyl)acetic acid, HA);
- Xaa7 is threonine (Thr, T) or isoleucine (Ile, I),
- Xaa12 is glutamic acid (Glu, E), isoleucine (Ile, I), lysine (Lys, K), or arginine (Arg, R);
- Xaa13 is alanine (Ala, A), Aib, tyrosine (Tyr, Y), or glutamine (Gln, Q);
- Xaa14 is methionine (Met, M) or leucine (Leu, L),
- Xaa15 is aspartic acid (Asp, D) or glutamic acid (Glu, E),
- Xaa16 is lysine (Lys, K), glutamic acid (Glu, E), alanine (Ala, A), or norleucine (Norleucine, Nle);
- Xaa17 is glutamic acid (Glu, E), isoleucine (Ile, I), lysine (Lys, K), arginine (Arg, R), or glutamine (Gln, Q);
- Xaa18 is alanine (Ala, A), arginine (Arg, R), or histidine (His, H);
- Xaa19 is valine (Val, V), alanine (Ala, A), glutamine (Gln, Q), serine (Ser, S), or cysteine (Cys, C);
- Xaa20 is arginine (Arg, R), lysine (Lys, K), Aib, or glutamine (Gln, Q);
- Xaa21 is glutamic acid (Glu, E), aspartic acid (Asp, D), alanine (Ala, A), leucine (Leu, L), or Aib;
- Xaa23 is isoleucine (Ile, I) or valine (Val, V),
- Xaa24 is alanine (Ala, A), glutamine (Gln, Q), serine (Ser, S), or asparagine (Asn, N);
- Xaa27 is valine (Val, V), leucine (Leu, L), or isoleucine (Ile, I);
- Xaa28 is lysine (Lys, K), aspartic acid (Asp, D), arginine (Arg, R), asparagine (Asn, N), alanine (Ala, A), or Aib;
- Xaa29 is glycine (Gly, G), histidine (His, H), or glutamine (Gin, Q);
- Xaa30 is glycine (Gly, G), histidine (His, H), lysine (Lys, K), or arginine (Arg, R);
- Xaa31 is proline (Pro, P) or glycine (Gly, G),
- Xaa32 is serine (Ser, S) or lysine (Lys, K),
- Xaa33 is serine (Ser, S) or lysine (Lys, K),
- Xaa34 is glycine (Gly, G), asparagine (Asn, N), or serine (Ser, S);
- Xaa35 is alanine (Ala, A), glutamine (Gln, Q), or aspartic acid (Asp, D);
- Xaa36 is proline (Pro, P) or tryptophan (Trp, W),
- Xaa37 is proline (Pro, P) or lysine (Lys, K),
- Xaa38 is proline (Pro, P) or histidine (His, H),
- Xaa39 is serine (Ser, S), cysteine (Cys, C), or asparagine (Asn, N);
- Xaa40 is cysteine (Cys, C), lysine (Lys, K), tyrosine (Tyr, Y), or isoleucine (Ile, I) or is absent;
- Xaa41 is lysine (Lys, K) or threonine (Thr, T) or absent;
- Xaa42 is glutamine (Gln, Q) or absent,
- Xaa43 is cysteine (Cys, C) or absent.
- Exemplary types of such peptides may include any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 44.
- the subsequent amino acid sequence may be absent.
- Xaa40 is absent
- Xaa41 to Xaa43 may be absent.
- Xaa42 to Xaa43 may be absent.
- the peptide may include an amino acid sequence represented by the following general formula 2:
- Xaa1 is tyrosine (Tyr, Y) or histidine (His, H),
- Xaa12 is isoleucine (Ile, I) or lysine (Lys, K),
- Xaa13 is alanine (Ala, A), Aib, or tyrosine (Tyr, Y),
- Xaa15 is aspartic acid (Asp, D) or glutamic acid (Glu, E),
- Xaa16 is lysine (Lys, K) or glutamic acid (Glu, E),
- Xaa17 is isoleucine (Ile, I), lysine (Lys, K), arginine (Arg, R), or glutamine (Gln, Q);
- Xaa18 is alanine (Ala, A), arginine (Arg, R),
- Xaa19 is alanine (Ala, A), glutamine (Gln, Q), or cysteine (Cys, C);
- Xaa20 is arginine (Arg, R), lysine (Lys, K), Aib, or glutamine (Gln, Q);
- Xaa21 is glutamic acid (Glu, E), aspartic acid (Asp, D), alanine (Ala, A), or Aib,
- Xaa24 is glutamine (Gln, Q) or asparagine (Asn, N);
- Xaa27 is leucine (Leu, L), or isoleucine (Ile, I),
- Xaa28 is aspartic acid (Asp, D), asparagine (Asn, N), or alanine (Ala, A),
- Xaa29 is glycine (Gly, G) or histidine (His, H);
- Xaa30 is glycine (Gly, G) or histidine (His, H);
- Xaa35 is alanine (Ala, A) or glutamine (Gln, Q),
- Xaa40 is cysteine (Cys, C), lysine (Lys, K), or tyrosine (Tyr, Y);
- Xaa41 is lysine (Lys, K) or absent.
- Exemplary types of such peptides may include any one amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 15, 16, 20, 36, 37, 38, and 40.
- Xaa1 is tyrosine (Tyr, Y),
- Xaa12 is isoleucine (Ile, I)
- Xaa13 is alanine (Ala, A) or Aib,
- Xaa15 is aspartic acid (Asp, D) or glutamic acid (Glu, E),
- Xaa16 is lysine (Lys, K),
- Xaa17 is glutamine (Gln, Q),
- Xaa18 is alanine (Ala, A)
- Xaa19 is alanine (Ala, A) or glutamine (Gln, Q),
- Xaa20 is arginine (Arg, R), Aib, or glutamine (Gln, Q);
- Xaa21 is aspartic acid (Asp, D) or alanine (Ala, A),
- Xaa24 is glutamine (Gln, Q) or asparagine (Asn, N);
- Xaa27 is leucine (Leu, L), or isoleucine (Ile, I),
- Xaa28 is alanine (Ala, A)
- Xaa29 is glycine (Gly, G),
- Xaa30 is glycine (Gly, G),
- Xaa35 is alanine (Ala, A)
- Xaa40 is cysteine (Cys, C),
- Xaa41 may be absent.
- An exemplary type of such a peptide may include any one amino acid sequence selected from the group consisting of SEQ ID NOs: 20, 36, and 40.
- R1 is absent
- Xaa1 is tyrosine (Tyr, Y),
- Xaa7 is threonine (Thr, T)
- Xaa12 is isoleucine (Ile, I)
- Xaa13 is alanine (Ala, A) or Aib,
- Xaa14 is leucine (Leu, L)
- Xaa15 is aspartic acid (Asp, D) or glutamic acid (Glu, E),
- Xaa16 is lysine (Lys, K),
- Xaa17 is glutamine (Gln, Q),
- Xaa18 is alanine (Ala, A)
- Xaa19 is glutamine (Gln, Q),
- Xaa20 is arginine (Arg, R), or glutamine (Gln, Q);
- Xaa21 is aspartic acid (Asp, D) or alanine (Ala, A),
- Xaa23 is valine (Val, V)
- Xaa24 is glutamine (Gln, Q) or asparagine (Asn, N);
- Xaa27 is leucine (Leu, L) or isoleucine (Ile, I),
- Xaa28 is alanine (Ala, A)
- Xaa29 is glycine (Gly, G),
- Xaa30 is glycine (Gly, G),
- Xaa31 is proline (Pro, P)
- Xaa32 is serine (Ser, S),
- Xaa33 is serine (Ser, S),
- Xaa34 is glycine (Gly, G),
- Xaa35 is alanine (Ala, A)
- Xaa36 is proline (Pro, P)
- Xaa37 is proline (Pro, P)
- Xaa38 is proline (Pro, P)
- Xaa39 is serine (Ser, S),
- Xaa40 is cysteine (Cys, C),
- Xaa41 to Xaa43 may be absent.
- the peptide may include any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 44.
- the peptide may be essentially composed of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 44, or the peptide may be composed of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 44 .
- the peptide may include any one amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 15, 16, 20, 36, 37, 38, and 40.
- the peptide consists essentially of any one amino acid sequence selected from the group consisting of SEQ ID NO: 14, 15, 16, 20, 36, 37, 38, and 40, or the peptide is SEQ ID NO: 14, 15, 16 , 20, 36, 37, 38, and 40 may be composed of any one amino acid sequence selected from the group consisting of.
- the peptide may include any one amino acid sequence selected from the group consisting of SEQ ID NOs: 20, 36, and 40.
- the peptide consists essentially of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 20, 36, and 40, or consists of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 20, 36, and 40 it could be
- the peptide has an amino acid sequence of SEQ ID NOs: 1 to 44 and 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83% , 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more It may include, but is not limited to, amino acid sequences having identity.
- “Homology” or “identity” refers to the degree to which two given amino acid sequences or base sequences are related to each other and can be expressed as a percentage. Whether any two peptide sequences have homology, similarity or identity can be determined, for example, by Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444, using a known computer algorithm such as the “FASTA” program. or, as performed in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later), Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol.
- GAP program is defined as the total number of symbols in the shorter of two sequences divided by the number of similarly aligned symbols (ie, amino acids).
- Default parameters for the GAP program are: (1) a binary comparison matrix (containing values of 1 for identity and 0 for non-identity) and Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp.
- the peptide according to any one of the preceding embodiments may include an intramolecular bridge, and specifically may be in a form including a ring.
- the intramolecular crosslinking may be, for example, a covalent crosslinking or a non-covalent crosslinking.
- amino acids 12 and 16, or amino acids 16 and 20 from the N-terminus in the peptide sequence may form a ring with each other, but are not particularly limited thereto. .
- the peptide according to any one of the preceding embodiments may be one in which Xaa12 and Xaa16, or Xaa16 and Xaa20 form a ring with each other, but is not particularly limited thereto.
- the peptides represented by SEQ ID NOs: 1, 12, and 13 may be in a form in which Xaa12 and Xaa16 form a ring with each other.
- the peptides represented by SEQ ID NOs: 2 to 11, 15, and 22 to 25 may be in a form in which Xaa16 and Xaa20 form a ring with each other.
- Non-limiting examples of the ring may include a lactam bridge (or lactam ring).
- a lactam bridge or lactam ring
- Such a ring may be formed between amino acid side chains in the peptide, for example, a lactam ring may be formed between a lysine side chain and a glutamic acid side chain, but is not particularly limited thereto.
- a peptide comprising the amino acid sequence of Formula 1 according to an aspect can be prepared by a combination of various methods for preparing various peptides.
- the peptide according to an aspect may be synthesized by a method well known in the art according to its length, for example, an automatic peptide synthesizer, or may be produced by a genetic engineering technique. Specifically, the peptide may be prepared by standard synthetic methods, recombinant expression systems, or any other method in the art. Accordingly, a peptide according to an aspect can be synthesized by a number of methods including, but not limited to, for example, methods including:
- a method for obtaining a fragment of a peptide by any combination of (a), (b) and (c), and then ligating the fragments to obtain a peptide, and recovering the peptide.
- the preparation of the peptide may include modification using L- or D-form amino acids, and/or non-natural amino acids; and/or by modifying the native sequence, e.g., modification of side chain functional groups, intramolecular covalent bonds, such as inter-side chain ring formation, methylation, acylation, ubiquitination, phosphorylation, aminohexylation, biotinylation, etc. includes all that Also, the above modifications include all substitutions with non-naturally occurring compounds.
- Substituted or added amino acids used in the above modification may use atypical or non-naturally occurring amino acids as well as the 20 amino acids commonly found in human proteins.
- Commercial sources of atypical amino acids may include, but are not limited to, Sigma-Aldrich, ChemPep and Genzyme pharmaceuticals.
- aminoisobutyric acid (Aib) may be prepared by synthesizing amino acids of Strecker in acetone, but is not limited thereto.
- Peptides containing such atypical or non-naturally occurring amino acids and canonical peptide sequences may be synthesized and purchased from commercial peptide synthesis companies, for example, American peptide company or Bachem in the United States, or Anygen in Korea, but limited thereto. doesn't happen
- the peptide may have an unmodified N-terminus and/or C-terminus, but its N-terminus and/or C-terminus may be chemically modified to protect it from proteolytic enzymes in vivo and to increase stability. Modified, protected with an organic group, or modified by adding amino acids to the end of the peptide, etc., are also included in the scope of the peptide according to the above aspect.
- the end of the peptide has a free carboxyl group, but is not particularly limited thereto.
- the N-terminus and/or the C-terminus may be modified to remove these charges.
- the N-terminus may be acetylated and/or the C-terminal amidation may be performed, but the present invention is not particularly limited thereto.
- the peptide may have its C-terminus unmodified or amidated, but is not limited thereto.
- the peptide includes both the peptide itself, a salt thereof (eg, a pharmaceutically acceptable salt of the peptide), or a solvate thereof.
- the type of the salt is not particularly limited. However, it is preferable that the form is safe and effective for an individual, such as a mammal, but is not particularly limited thereto.
- the peptide may be in any pharmaceutically acceptable form.
- pharmaceutically acceptable means that it does not cause side effects and in an amount sufficient to exhibit a therapeutic effect, the type of disease, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the route of administration , can be easily determined by those skilled in the art according to factors well known in the medical field, such as administration method, number of administration, treatment period, combination or concurrently used drugs.
- the peptide may be in the form of a pharmaceutically acceptable salt thereof.
- the salts include conventional acid addition salts used in the pharmaceutical field, for example, in the field of treating diabetes, for example, salts derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid or nitric acid; and acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, citric acid, maleic acid, malonic acid, methanesulfonic acid, tartaric acid, malic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, oxalic acid or salts derived from organic acids such as trifluoroacetic acid.
- inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric
- the salt may be a base addition salt such as ammonium, dimethylamine, monomethylamine, monoethylamine, or diethylamine.
- the salts also include conventional metal salt forms, for example salts derived from metals such as lithium, sodium, potassium, magnesium, or calcium.
- the acid addition salt, base addition salt or metal salt may be prepared according to a conventional method.
- Pharmaceutically acceptable salts and general methodologies for their preparation are well known in the art. For example, in P. Stahl, et al. Handbook of Pharmaceutical Salts: Properties, Selection and Use, 2nd Revised Edition (Wiley-VCH, 2011)]; [S.M. Berge, et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, Vol. 66, No. 1, January 1977].
- triphosphonium salts include benzotriazol-1-yloxytris (pyrrolagino) phosphonium hexafluorophosphate (PyBOP), bromotris (pyrrolazino) phosphonium hexafluorophosphate (PyBroP), 7 -Azabenzotriazol-1-yloxytris(pyrrolazino)phosphonium hexafluorophosphate (PyAOP), examples of tetramethyluronium salts are 2-(1H-benzotriazol-1-yl)- 1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 2-(7-azabenzotriazol-1-yl)-1,1,3,3-
- racemization inhibitors eg, N-hydroxy-5-norbornene-2,3-dicarboxylic acid imide (HONB), 1-hydroxybenzotriazole (HOBt), 1-hydroxy- 7-azabenzotriazole (HOAt), 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HOOBt), ethyl 2-cyano-2- (hydroxyl mino)acetate (Oxyma), etc.
- the solvent used for the condensation may be appropriately selected from those known to be useful for the peptide condensation reaction.
- acid amides such as anhydrous or water-containing N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, etc.; Alcohols such as fluoroethanol and phenol, sulfoxides such as dimethylsulfoxide, tertiary amines such as pyridine, ethers such as dioxane and tetrahydrofuran, nitriles such as acetonitrile, propionitrile, methyl acetate, ethyl Esters such as acetates and the like, suitable mixtures thereof, and the like can be used.
- Alcohols such as fluoroethanol and phenol, sulfoxides such as dimethylsulfoxide, tertiary amines such as pyridine, ethers such as dioxane and tetrahydrofuran, nitriles such as acet
- the reaction temperature is appropriately selected from a range known to be usable for a peptide binding reaction, and is usually selected from the range of about -20°C to 90°C.
- Activated amino acid derivatives are usually used in 1.5 to 6-fold excess.
- solid-phase synthesis when the test using the ninhydrin reaction indicates that the condensation is insufficient, sufficient condensation can be carried out by repeating the condensation reaction without removing the protecting group. If the condensation is still insufficient after repeating the reaction, the unreacted amino acid may be acetylated with an acid anhydride, acetylimidazole, or the like, so that the influence on the subsequent reaction can be avoided.
- protecting groups for the amino group of the starting amino acid are benzyloxycarbonyl (Z), tert-butoxycarbonyl (Boc), tert-pentyloxycarbonyl, isobornyloxycarbonyl, 4-methoxybenzyloxycarbonyl , 2-chlorobenzyloxycarbonyl (Cl-Z), 2-bromobenzyloxycarbonyl (Br-Z), adamantyloxycarbonyl, trifluoroacetyl, phthaloyl, formyl, 2-nitro phenylsulfenyl, diphenylphosphinothioyl, 9-fluorenylmethyloxycarbonyl (Fmoc), trityl, and the like.
- Examples of a carboxyl-protecting group for the starting amino acid include, in addition to the above-mentioned C 1-6 alkyl group, C 3-10 cycloalkyl group, C 7-14 aralkyl group, aryl, 2-adamantyl, 4-nitrobenzyl, 4 -methoxybenzyl, 4-chlorobenzyl, phenacyl and benzyloxycarbonylhydrazide, tert-butoxycarbonylhydrazide, tritylhydrazide and the like.
- the hydroxyl group of serine or threonine may be protected, for example, by esterification or etherification.
- groups suitable for esterification include lower (C 2-4 ) alkanoyl groups such as acetyl groups, aroyl groups such as benzoyl groups, and groups derived from organic acids and the like.
- suitable groups for etherification include benzyl, tetrahydropyranyl, tert-butyl (But t ), trityl (Trt), and the like.
- Examples of the protecting group for the phenolic hydroxyl group of tyrosine include Bzl, 2,6-dichlorobenzyl, 2-nitrobenzyl, Br-Z, tert-butyl and the like.
- Examples of the protecting group of histidine for imidazole include p-toluenesulfonyl (Tos), 4-methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr), dinitrophenyl (DNP), benzyloxymethyl (Bom), tert-butoxymethyl (Bum), Boc, Trt, Fmoc, and the like.
- Examples of protecting groups for the guanidino group of arginine include Tos, Z, 4-methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr), p-methoxybenzenesulfonyl (MBS), 2,2, 5,7,8-pentamethylchroman-6-sulfonyl (Pmc), mesitylene-2-sulfonyl (Mts), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl phonyl (Pbf), Boc, Z, NO 2 and the like.
- Mtr 4-methoxy-2,3,6-trimethylbenzenesulfonyl
- MSS p-methoxybenzenesulfonyl
- Pmc 2,2, 5,7,8-pentamethylchroman-6-sulfonyl
- Mts mesitylene-2-sulfonyl
- Pbf 2,2,4,6,7-p
- Examples of a protecting group for the side chain amino group of lysine include Z, Cl-Z, trifluoroacetyl, Boc, Fmoc, Trt, Mtr, 4,4-dimethyl-2,6-dioxocyclohexylidenyl (Dde), etc. includes
- Examples of the protecting group for indolyl of tryptophan include formyl (For), Z, Boc, Mts, Mtr, and the like.
- protecting groups for asparagine and glutamine include Trt, xantyl (Xan), 4,4'-dimethoxybenzhydryl (Mbh), 2,4,6-trimethoxybenzyl (Tmob), and the like.
- activated carboxyl groups in the starting material include the corresponding acid anhydrides, azides, active esters [esters with alcohols (eg pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol) , cyanomethyl alcohol, paranitrophenol, HONB, N-hydroxysucciimide, 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt))] include Examples of activated amino groups in the starting material include the corresponding phosphorus amides.
- Examples of methods for removing protecting groups include catalytic reduction in a hydrogen stream in the presence of a catalyst such as Pd-black or Pd-carbon; Anhydrous hydrogen fluoride, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid (TFA), trimethylsilyl bromide (TMSBr), trimethylsilyl trifluoromethanesulfonate, tetrafluoroboric acid, tris(tris) acid treatment with a solution of fluoro)boric acid, boron tribromide, or a mixture thereof; base treatment with diisopropylethylamine, triethylamine, piperidine, piperazine or the like; and reduction with sodium in liquid ammonia and the like.
- a catalyst such as Pd-black or Pd-carbon
- Anhydrous hydrogen fluoride methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid (TFA
- the removal reaction by acid treatment described above is generally carried out at a temperature of -20°C to 40°C; Acid treatments include anisole, phenol, thioanisole, methacresol and paracresol; This is done efficiently by adding a cation scavenger such as dimethylsulfide, 1,4-butanedithiol, 1,2-ethanedithiol, triisopropylsilane, and the like.
- a cation scavenger such as dimethylsulfide, 1,4-butanedithiol, 1,2-ethanedithiol, triisopropylsilane, and the like.
- the 2,4-dinitrophenyl group used as the protecting group of imidazole of histidine is removed by thiophenol treatment;
- the formyl group used as the protecting group of the indole of tryptophan is not only by acid treatment in the presence of 1,2-ethanedithiol, 1,4-butanedithiol, etc., but also by alkali treatment with diluted sodium hydroxide, diluted ammonia, etc. It is removed by deprotection.
- Protection of a functional group that should not be involved in the reaction between the starting material and the protecting group, removal of the protecting group, activation of the functional group involved in the reaction, and the like may be appropriately selected from known protecting groups and known means.
- the left end is the N-terminal (amino terminus) and the right end is the C-terminus (carboxyl terminus) according to conventional peptide markings.
- the C-terminus of the peptide is an amide (-CONH 2 ), a carboxyl group (-COOH), a carboxylate (-COO-), an alkylamide (-CONHR′, where R′ is alkyl) and an ester (-COOR′,
- R' may be any one of alkyl or aryl.
- an amide of a peptide it is formed by solid-phase synthesis using a resin for amide synthesis, or the ⁇ -carboxyl group of a carboxy-terminal amino acid is amidated, and the peptide chain is extended to the desired chain length toward the amino group. Then, a peptide in which the protecting group for the N-terminal ⁇ -amino group of only the peptide chain has been removed and the peptide with only the protecting group for the C-terminal carboxyl group removed from the peptide chain are prepared, and these two peptides are mixed as described above condensed in a solvent. As for the details of the condensation reaction, the same applies as described above.
- the peptide may be in the form of a solvate thereof.
- “Solvate” means that the peptide or a salt thereof forms a complex with a solvent molecule.
- Another aspect provides a polynucleotide encoding the GLP-1/GIP dual agonist.
- the GLP-1/GIP dual agonist is the same as described above.
- the polynucleotide may be an isolated polynucleotide.
- the polynucleotide includes DNA and RNA encoding a target protein.
- the polynucleotide may be modified. Such modifications include additions, deletions, or non-conservative or conservative substitutions of nucleotides.
- the polynucleotide may be composed of a nucleotide sequence having 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more sequence identity with the corresponding sequence. .
- Another aspect provides a vector comprising the polynucleotide.
- vector refers to a means for expressing a gene of interest in a host cell.
- examples include viral vectors such as plasmid vectors, cosmid vectors, bacteriophage vectors, adenovirus vectors, retrovirus vectors and adeno-associated viral vectors.
- Vectors that can be used as the recombinant vector include plasmids often used in the art (eg, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14.
- plasmid is currently the most commonly used form of vector, "plasmid” and “vector” are sometimes used interchangeably herein.
- the polynucleotide encoding the GLP-1/GIP dual agonist may be operably linked to a promoter.
- operably linked means that the polynucleotide sequence is functionally linked to a promoter sequence that initiates and mediates transcription of a polynucleotide encoding a target protein.
- the recombinant vector can typically be constructed as a vector for cloning or as a vector for expression.
- the expression vector may be a conventional vector used to express a foreign protein in plants, animals or microorganisms in the art.
- the recombinant vector can be constructed through various methods known in the art.
- the recombinant vector can be constructed using a prokaryotic cell or a eukaryotic cell as a host.
- a strong promoter capable of propagating transcription eg, pL ⁇ promoter, trp promoter, lac promoter, tac promoter, T7 promoter, etc.
- translation It is common to include a ribosome binding site and transcription/translation termination sequence for initiation of
- the replication origin operating in the eukaryotic cell included in the vector includes the f1 origin of replication, SV40 origin of replication, pMB1 origin of replication, adeno origin of replication, AAV origin of replication, CMV origin of replication and BBV origin of replication.
- promoters derived from the genome of mammalian cells eg, metallotionine promoter
- mammalian viruses eg, adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, The cytomegalovirus (CMV) promoter and the tk promoter of HSV
- CMV cytomegalovirus
- Another aspect provides a host cell comprising the polynucleotide or vector.
- the host cell may be an isolated cell.
- a host cell that can be transformed with a recombinant vector a host with high DNA introduction efficiency and high expression efficiency of the introduced DNA is usually used.
- Well-known eukaryotic and prokaryotic hosts e.g. E. coli, Pseudomonas, Bacillus, Streptomyces, fungi, yeast, insect cells such as Spodoptera frugiperda (SF 9), CHO, COS 1, COS 7, Animal cells such as BSC 1, BSC40, and BMT 10 may be used, but the present invention is not limited thereto.
- Insertion of a polynucleotide or a recombinant vector containing the same into a host cell may use a method well known in the art.
- the transport method is, for example, when the host cell is a prokaryotic cell, calcium chloride (CaCl 2 ) method or electroporation method can be used, and when the host cell is a eukaryotic cell, microinjection method, calcium phosphate precipitation method, electrophoresis Perforation, liposome-mediated transfection, and gene bombardment may be used, but are not limited thereto.
- the polynucleotide may be introduced into a host cell in the form of an expression cassette, which is a gene construct including all elements necessary for self-expression.
- the expression cassette may include a promoter operably linked to the polynucleotide, a transcription termination signal, a ribosome binding site, and a translation termination signal.
- the expression cassette may be in the form of an expression vector capable of self-replication.
- the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence required for expression in the host cell, but is not limited thereto.
- Another aspect provides a conjugate in which the GLP-1/GIP dual agonist and a biocompatible material that increases the in vivo half-life are combined.
- the GLP-1/GIP dual agonist is the same as described above.
- the biocompatible material may be mixed with a carrier.
- the binder may be an isolated binder.
- the conjugate exhibits an activity equivalent to or higher than that of a native ligand (ie, native GLP-1 and native GIP), and at the same time can exhibit increased potency and durability compared to a native ligand or a derivative thereof to which a carrier is not bound.
- the binder may be a long-acting binder.
- the term “long-acting conjugate” refers to a conjugate with increased durability of efficacy compared to a natural GIP or GIP derivative to which a biocompatible material is not bound.
- the conjugate is a “long-acting GLP-1/GIP dual agonist conjugate”, “a long-acting GLP-1/GIP dual agonist”, “long-acting GLP-1/GIP conjugate”, “a long-acting dual agonist conjugate”, “dual agent conjugate”, “long-acting conjugate”, “conjugate” can be used interchangeably.
- a binder includes not only the above-described form, but also a form encapsulated in biodegradable nanoparticles.
- the combination may be non-naturally occurring.
- the biocompatible material may be bonded to the GLP-1/GIP double agent by a covalent chemical bond or a non-covalent chemical bond, and to each other through a linker (Linker, L) through a covalent chemical bond, a non-covalent chemical bond, or a combination thereof. may be combined.
- Linker L
- One or more amino acid side chains in the GLP-1/GIP dual agonist may be conjugated to such biocompatible materials to increase solubility and/or half-life and/or increase bioavailability in vivo. Such modifications may also reduce clearance of therapeutic proteins and peptides.
- the biocompatible material described above may be water-soluble (amphiphilic or hydrophilic) and/or non-toxic and/or pharmaceutically acceptable.
- the biocompatible material is a high molecular polymer, fatty acid, cholesterol, albumin and fragments thereof, albumin binding material, a polymer of a repeating unit of a specific amino acid sequence, antibody, antibody fragment, FcRn binding material, connective tissue in vivo, nucleotide, fibronectin, transferrin ( Transferrin), saccharides (saccharide), heparin, and may be selected from the group consisting of elastin, but is not particularly limited thereto.
- polymer polymer examples include polyethylene glycol (PEG), polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, and a high molecular polymer selected from the group consisting of hyaluronic acid, oligonucleotides, and combinations thereof, and the polysaccharide may include dextran, but is not particularly limited thereto.
- PEG polyethylene glycol
- polypropylene glycol ethylene glycol-propylene glycol copolymer
- polyoxyethylated polyol polyvinyl alcohol
- polysaccharide polyvinyl ethyl ether
- biodegradable polymer lipid polymer
- chitin examples of the polysaccharide may include dextran, but is not particularly limited thereto.
- the polyethylene glycol is a term encompassing all forms of ethylene glycol homopolymer, PEG copolymer, or monomethyl-substituted PEG polymer (mPEG), but is not particularly limited thereto.
- the fatty acid may have a binding force with albumin in vivo, but is not particularly limited thereto.
- the biocompatible materials include, but are not limited to, poly-amino acids such as poly-lysine, poly-aspartic acid and poly-glutamic acid.
- the elastin may be human tropoelastin, a water-soluble precursor, and may be a polymer of some sequences or some repeating units of these, for example, all of the cases of elastin-like polypeptides, but is not particularly limited thereto. .
- the biocompatible material may be an FcRn binding material.
- the FcRn-binding material may be an immunoglobulin Fc region, more specifically an IgG Fc region, more specifically an aglycosylated IgG4 Fc region, but is not particularly limited thereto.
- Immunoglobulin Fc region refers to a region comprising a heavy chain constant region 2 (CH2) and/or heavy chain constant region 3 (CH3) region, excluding the heavy and light chain variable regions of an immunoglobulin.
- the immunoglobulin Fc region may be a component constituting a moiety of the conjugate according to an aspect.
- the immunoglobulin Fc region may include a hinge region in the heavy chain constant region, but is not limited thereto.
- the immunoglobulin Fc region may include a specific hinge sequence at the N-terminus.
- flankinge sequence refers to a region that is located in the heavy chain and forms a dimer of an immunoglobulin Fc fragment through an inter disulfide bond.
- the hinge sequence may be mutated to have only one cysteine residue by deleting a portion of the hinge sequence having the following amino acid sequence, but is not limited thereto:
- the hinge sequence may include only one cysteine residue by deleting the 8th or 11th cysteine residue in the hinge sequence of SEQ ID NO: 45.
- the hinge sequence according to one embodiment may be composed of 3 to 12 amino acids, including only one cysteine residue, but is not limited thereto.
- the hinge sequence may have the following sequence: Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Pro-Ser-Cys-Pro (SEQ ID NO: 46), Glu- Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser-Pro (SEQ ID NO: 47), Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser (SEQ ID NO: 48), Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Pro (SEQ ID NO: 49), Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser (SEQ ID NO: 50), Glu-Ser- Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser (SEQ ID NO: 51), Glu-Lys-Tyr-Gly-Pro-Pro-Cys (SEQ ID NO: 52
- the hinge sequence may include the amino acid sequence of SEQ ID NO: 55 (Pro-Ser-Cys-Pro) or SEQ ID NO: 64 (Ser-Cys-Pro), but is not limited thereto.
- the immunoglobulin Fc region may have a form in which two molecules of an immunoglobulin Fc chain form a dimer due to the presence of a hinge sequence.
- the conjugate of Formula 1 may be in a form in which one end of the linker is linked to one chain of the dimer immunoglobulin Fc region, but is not limited thereto.
- N-terminus refers to the amino terminus of a protein or polypeptide, and 1, 2, 3, 4, 5, 6, 7, 8 Dogs, 9, or may include up to 10 or more amino acids.
- the immunoglobulin Fc fragment of the present invention may include a hinge sequence at the N-terminus, but is not limited thereto.
- part or all of the heavy chain constant region 1 (CH1) and/or the light chain constant region 1 except for only the heavy and light chain variable regions of the immunoglobulin (CL1) may be an extended Fc region. Also, it may be a region in which some fairly long amino acid sequences corresponding to CH2 and/or CH3 have been removed.
- the immunoglobulin Fc region comprises (a) a CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain; (b) a CH1 domain and a CH2 domain; (c) a CH1 domain and a CH3 domain; (d) a CH2 domain and a CH3 domain; (e) a combination of one or more domains of a CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain with an immunoglobulin hinge region or portion of a hinge region; And (f) it may be selected from the group consisting of a dimer of each domain of the heavy chain constant region and the light chain constant region, but is not limited thereto.
- the immunoglobulin Fc region may be in a dimeric form, and one molecule of the GLP-1/GIP dual agonist may be covalently linked to one Fc region in the dimeric form, wherein the immunoglobulin Fc and GLP- 1/GIP dual agonists may be linked to each other by non-peptidyl polymers.
- the immunoglobulin Fc and the GLP-1/GIP dual agonist may be linked to each other by a non-peptidyl linker.
- the immunoglobulin Fc region includes a native amino acid sequence as well as a sequence derivative thereof.
- An amino acid sequence derivative means that one or more amino acid residues in a natural amino acid sequence have a different sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof.
- amino acid residues 214 to 238, 297 to 299, 318 to 322, or 327 to 331 known to be important for binding may be used as suitable sites for modification.
- various types of derivatives are possible, such as a site capable of forming a disulfide bond is removed, some amino acids at the N-terminus of native Fc are removed, or a methionine residue may be added to the N-terminus of native Fc Do.
- the complement binding site for example, the C1q binding site, may be removed, or the ADCC (antibody dependent cell mediated cytotoxicity) site may be removed.
- Techniques for preparing such an immunoglobulin Fc region sequence derivative are disclosed in International Patent Publication Nos. WO 97/34631 and International Patent Publication No. 96/32478.
- the above-described Fc derivative may exhibit the same biological activity as that of the Fc region and increase structural stability against heat, pH, etc. of the Fc region.
- the Fc region may be obtained from a native type isolated in vivo from animals such as humans, cows, goats, pigs, mice, rabbits, hamsters, rats or guinea pigs, or obtained from transformed animal cells or microorganisms. It may be recombinant or a derivative thereof.
- the method of obtaining from the native type may be a method of obtaining whole immunoglobulin by isolating it from a living body of a human or animal and then treating it with a proteolytic enzyme. When treated with papain, it is cleaved into Fab and Fc, and when treated with pepsin, it is cleaved into pF'c and F(ab) 2 .
- Fc or pF'c may be separated using size-exclusion chromatography or the like.
- the human-derived Fc region is a recombinant immunoglobulin Fc region obtained from a microorganism.
- the immunoglobulin Fc region may have a native sugar chain, an increased sugar chain compared to the native type, a decreased sugar chain compared to the native type, or a form in which the sugar chain is removed.
- Conventional methods such as chemical methods, enzymatic methods, and genetic engineering methods using microorganisms may be used for the increase or decrease or removal of such immunoglobulin Fc sugar chains.
- the immunoglobulin Fc region from which the sugar chains are removed from the Fc has significantly reduced binding to complement (c1q) and reduced or eliminated antibody-dependent cytotoxicity or complement-dependent cytotoxicity, so that unnecessary immune responses in vivo are not induced.
- a form more suitable for the original purpose as a drug carrier may be an immunoglobulin Fc region in which sugar chains are removed or non-glycosylated.
- Deglycosylation refers to an Fc region from which sugars are removed by an enzyme, and aglycosylation refers to an Fc region that is not glycosylated by being produced in a prokaryote, in a more specific embodiment, in E. coli.
- the immunoglobulin Fc region may be an Fc region derived from IgG, IgA, IgD, IgE, or IgM, or a combination or hybrid thereof. In a more specific embodiment, it is derived from IgG or IgM, which is most abundant in human blood, and in a more specific embodiment it is derived from IgG, which is known to enhance the half-life of ligand binding proteins. In a still more specific embodiment, the immunoglobulin Fc region is an IgG4 Fc region, and in the most specific embodiment, the immunoglobulin Fc region is an aglycosylated Fc region derived from human IgG4, but is not limited thereto.
- “Combination” means that, when forming dimers or multimers, polypeptides encoding single-chain immunoglobulin Fc regions of the same origin form bonds with single-chain polypeptides of different origins. That is, it is possible to prepare a dimer or multimer from two or more fragments selected from the group consisting of IgG Fc, IgA Fc, IgM Fc, IgD Fc and IgE Fc fragment.
- the GLP-1/GIP dual agonist may be linked to a biocompatible material through a linker.
- the linker may be a peptidic linker or a non-peptidyl linker.
- the linker when the linker is a peptidic linker, it may include one or more amino acids, for example, 1 to 1000 amino acids, but is not particularly limited thereto.
- the peptidic linker may include Gly, Asn and Ser residues, and neutral amino acids such as Thr and Ala may also be included.
- various known peptide linkers may be used.
- the copy number “n” can also be adjusted to achieve proper separation between functional moieties or to allow for optimization of the linker to maintain the necessary inter-moiety interactions.
- Other flexible linkers are known in the art, for example, G and S linkers to which amino acid residues such as T and A are added to maintain flexibility as well as polar amino acid residues to improve water solubility.
- the linker may be a flexible linker comprising G, S, and/or T residues.
- linkers include (GGGGS)n, (SGGGG)n, (SRSSG)n, (SGSSC)n, (GKSSGSGSESKS)n, (RPPPPC)n, (SSPPPPC)n, (GSTSGSGKSSEGKG)n, (GSTSGSGKSSEGSGSSTKG) n, (GSTSGSGKPGSGEGSTKG)n, or (EGKSSGSGSESKEF)n, wherein n is an integer of 1 to 20, or 1 to 10.
- non-peptidyl linker includes a biocompatible polymer to which two or more repeating units are linked.
- the repeating units are linked to each other through any covalent bond other than a peptide bond.
- the non-peptidyl linker may be a component constituting a moiety of the conjugate.
- non-peptidyl linker may be used interchangeably with “non-peptidyl polymer”.
- the conjugate comprises a biocompatible material, specifically, an immunoglobulin Fc region, and a non-peptidyl linker comprising a reactive group capable of binding to a GLP-1/GIP dual agonist at both ends of the biocompatible material and GLP -1/GIP dual agonists may be covalently linked to each other.
- non-peptidyl linker may be selected from the group consisting of fatty acids, saccharides, high molecular weight polymers, low molecular weight compounds, nucleotides, and combinations thereof.
- the non-peptidyl linker is polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, polyvinyl ethyl ether, polylactic acid (PLA) and It may be selected from the group consisting of biodegradable polymers such as polylactic-glycolic acid (PLGA), lipid polymers, chitins, hyaluronic acid, oligonucleotides, and combinations thereof.
- the polysaccharide may be dextran, but is not limited thereto.
- the non-peptidyl polymer may be, but is not limited to, polyethylene glycol.
- the linker may contain an ethylene glycol repeating unit.
- derivatives thereof already known in the art and derivatives that can be easily prepared at the level of skill in the art are also included in the scope of the present invention.
- the non-peptidyl linker may be used without limitation as long as it is a polymer resistant to proteolytic enzymes in vivo.
- the formula weight of the non-peptidyl polymer is in the range of 1 to 1000 kDa, specifically in the range of 1 to 100 kDa, more specifically in the range of 1 to 20 kDa, but is not limited thereto.
- the non-peptidyl linker not only one type of polymer, but also a combination of different types of polymers may be used.
- the formula weight of the ethylene glycol repeating unit moiety may be in the range of 1 to 100 kDa, more specifically, in the range of 1 to 20 kDa.
- both ends of the non-peptidyl linker may be bound to a biocompatible material, such as an amine group or a thiol group of an immunoglobulin Fc region, and an amine group or a thiol group of the GLP-1/GIP dual agonist, respectively.
- a biocompatible material such as an amine group or a thiol group of an immunoglobulin Fc region, and an amine group or a thiol group of the GLP-1/GIP dual agonist, respectively.
- the non-peptidyl polymer has a reactive group capable of binding to a biocompatible material (eg, immunoglobulin Fc region) and a GLP-1/GIP dual agonist at both ends, specifically, a GLP-1/GIP dual agonist,
- a biocompatible material eg, immunoglobulin Fc region
- the biocompatible material may include a reactive group capable of binding to an amine group located at the N-terminus or lysine, or a thiol group of cysteine, but is not limited thereto.
- the reactive group of the non-peptidyl polymer capable of binding to a biocompatible material, such as an immunoglobulin Fc region and a GLP-1/GIP dual agonist, may be selected from the group consisting of an aldehyde group, a maleimide group and a succinimide derivative.
- the aldehyde group may be exemplified by a propionaldehyde group or a butyl aldehyde group, but is not limited thereto.
- succinimidyl valerate succinimidyl methylbutanoate, succinimidyl methylpropionate, succinimidyl butanoate, succinimidyl propionate, N-hydroxysuccini Mead, hydroxy succinimidyl, succinimidyl carboxymethyl or succinimidyl carbonate may be used, but are not limited thereto.
- the final product resulting from reductive alkylation with aldehyde bonds is much more stable than those linked with amide bonds.
- the aldehyde reactive group selectively reacts with the N-terminus at a low pH, and can form a covalent bond with a lysine residue at a high pH, for example, pH 9.0.
- the reactive groups at both ends of the non-peptidyl linker may be the same or different from each other, for example, a maleimide group at one end and an aldehyde group, a propionaldehyde group, or a butyl aldehyde group at the other end.
- a biocompatible material specifically, an immunoglobulin Fc region and a GLP-1/GIP dual agonist can be bound to each end of the non-peptide linker, it is not particularly limited thereto.
- one end of the non-peptidyl linker may include a maleimide group as a reactive group, and an aldehyde group, a propionaldehyde group, or a butyl aldehyde group at the other end of the non-peptidyl linker.
- the hydroxyl group can be activated into the various reactive groups by a known chemical reaction, or using a commercially available polyethylene glycol having a modified reactive group. Long-acting binders can be prepared.
- the non-peptidyl polymer may be linked to a cysteine residue of a GLP-1/GIP dual agonist, more specifically, to a -SH group of cysteine, but is not limited thereto.
- maleimide-PEG-aldehyde is used, the maleimide group is connected to the -SH group of the GLP-1/GIP dual agonist by a thioether bond, and the aldehyde group is linked to the -SH group of a biocompatible material, specifically, immunoglobulin Fc - It may be connected through a reductive alkylation reaction with the NH 2 group, but is not limited thereto, and this corresponds to one example.
- the reactive group of the non-peptidyl polymer may be linked to -NH 2 located at the N-terminus of the immunoglobulin Fc region, but this corresponds to one example.
- binder according to the one aspect may be represented by the following Chemical Formula 1:
- X is a GLP-1 / GIP dual agonist
- L is a linker
- F is a biocompatible material that increases the in vivo half-life of X
- the GLP-1/GIP dual agent, the linker, and the biocompatible material are as described above.
- L may be La, wherein a is 0 or a natural number, provided that when a is 2 or more, each L may be independent of each other.
- the linker may be polyethylene glycol (PEG) represented by the following formula (2), but is not limited thereto:
- the PEG moiety in the long-acting conjugate may include, but is not limited to, the -(CH2CH2O)n- structure as well as an oxygen atom intervening between the linking element and the -(CH2CH2O)n-.
- the polyethylene glycol is a term encompassing all forms of ethylene glycol homopolymer, PEG copolymer, or monomethyl-substituted PEG polymer (mPEG), but is not particularly limited thereto.
- the - may represent a covalent linkage between X and L and between L and F.
- the GLP-1/GIP dual agonist or long-acting conjugate thereof has glycemic control ability in normal mice and exhibits an effect of reducing blood sugar and improving insulin resistance in diabetic model rats, and thus can be used for preventing or treating diabetes.
- Another aspect provides a pharmaceutical composition for preventing or treating diabetes, comprising the GLP-1/GIP dual agonist, a pharmaceutically acceptable salt or solvate thereof, or the conjugate.
- the GLP-1/GIP dual agonist, a pharmaceutically acceptable salt or solvate thereof, or the conjugate thereof is the same as described above.
- prevention refers to any action that suppresses or delays the onset of a disease by administration of the composition.
- treatment refers to any action in which the symptoms of a disease are improved or beneficial by administration of the composition.
- diabetes diabetes mellitus
- type 1 diabetes in which insulin is relatively insufficient, is characterized by insulin resistance (insulin resistance; the inability of cells to effectively burn glucose due to a lack of insulin function to lower blood sugar).
- insulin resistance insulin resistance; the inability of cells to effectively burn glucose due to a lack of insulin function to lower blood sugar.
- environmental factors such as a high-calorie, high-fat, high-protein diet, lack of exercise, and stress due to westernization of diet seem to play a major role. It can also be caused by infection or medication.
- the diabetes may be type 2 diabetes.
- the GLP-1/GIP dual agonist or a long-acting conjugate thereof showed blood sugar control ability in normal mice, and showed effects of reducing blood sugar, reducing glycated hemoglobin level, and improving insulin resistance in diabetic model rats, so not only diabetes but also diabetic complications , or for the prevention or treatment of insulin resistance and other diseases associated with diabetes.
- the pharmaceutical composition may be a pharmaceutical composition for preventing or treating diabetic complications.
- diabetes complications refers to various pathological symptoms accompanying the body while maintaining a high blood sugar state for a long time, for example, retinopathy, renal dysfunction, neuropathy, stroke, arteriosclerosis, cerebral infarction, cerebral thrombosis, myocardial infarction, Hypertension, kidney, heart disease or diabetic foot ulcer, and cardiovascular disease, but not limited thereto.
- the pharmaceutical composition may be a pharmaceutical composition for preventing or treating metabolic syndrome.
- the metabolic syndrome may be a metabolic syndrome associated with insulin resistance and diabetes.
- the metabolic syndrome may include dyslipidemia associated with insulin resistance and diabetes, obesity, and/or hepatic steatosis, and the like.
- the pharmaceutical composition may further include a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers may include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, dyes and fragrances, etc. for oral administration, and in the case of injections, buffers, preservatives, pain relief Agents, solubilizers, isotonic agents and stabilizers may be mixed and used.
- bases, excipients, lubricants and preservatives may be used for topical administration.
- the pharmaceutical composition may further include a pharmaceutically acceptable excipient.
- the dosage form of the pharmaceutical composition may be prepared in various ways by mixing with a pharmaceutically acceptable carrier as described above.
- a pharmaceutically acceptable carrier for example, in the case of oral administration, it may be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups and wafers, and in the case of injections, it may be prepared in the form of unit dose ampoules or multiple doses.
- it can be formulated into solutions, suspensions, tablets, pills, capsules, sustained-release preparations, and the like.
- suitable carriers, excipients and diluents for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl Cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil may be used.
- fillers, anti-agglomeration agents, lubricants, wetting agents, flavoring agents, emulsifiers and preservatives and the like may be further included.
- the pharmaceutical composition may further include one or more other agents for treating diabetes, diabetic complications, or metabolic syndrome.
- known substances may be used for the preparation.
- the dosage and frequency of administration of the pharmaceutical composition is determined according to the type of drug as an active ingredient, along with several related factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient, and the severity of the disease.
- the pharmaceutical composition Since the pharmaceutical composition has excellent in vivo persistence and potency, it is possible to significantly reduce the number and frequency of administration.
- Another aspect is diabetes, comprising administering to an individual in need thereof an effective amount of the GLP-1 / GIP dual agonist, a pharmaceutically acceptable salt, a solvate thereof, or the conjugate, or the pharmaceutical composition. to provide a method for preventing or treating
- the method may be a method for preventing or treating diabetic complications.
- the method may be a method for preventing or treating metabolic syndrome.
- the GLP-1/GIP dual agonist, a pharmaceutically acceptable salt thereof, a solvate thereof, the conjugate, the pharmaceutical composition, diabetes, diabetic complications, and metabolic syndrome are as described above.
- an “effective amount” or “pharmaceutically effective amount” means the GLP-1/GIP dual agonist, a pharmaceutically acceptable salt thereof, which, when administered to the patient in single or multiple doses, provides the desired effect in the patient under diagnosis or treatment; refers to the amount or dose of a solvate thereof, or a combination thereof.
- An effective amount can be readily determined by the attending physician of ordinary skill in the art by using known techniques or by observing the results obtained under similar circumstances.
- the mammalian species When determining an effective amount for a patient, the mammalian species; his size, age and general health; the specific disease or disorder involved; degree or severity of involvement of the disease or disorder; individual patient response; the particular compound being administered; mode of administration; the bioavailability characteristics of the agent being administered; selected dosing regimen; use of concomitant medications; and other relevant circumstances are considered by the attending physician.
- “Individual” means a subject in need of treatment for a disease, and more specifically, refers to mammals such as human or non-human primates, mice, rats, dogs, cats, horses and cattle. .
- administering means introducing a given substance into a patient by any suitable method.
- the route of administration may be any general route capable of reaching the in vivo target of the patient.
- the administration may be, for example, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, or rectal administration, but is not limited thereto.
- the administration is 0.0001 mg to 1,000 mg, for example, 0.1 mg to 1,000 mg, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, or 1 mg to 25 mg may be administered.
- the dosage may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and reaction sensitivity, and those skilled in the art The dosage may be appropriately adjusted in consideration of these factors.
- the number of administration may be once a day or twice or more within the range of clinically acceptable side effects, and may be administered to one or two or more sites for the administration site, and total daily or at intervals of 2 to 5 days
- the number of days of administration may range from 1 to 30 days per treatment. If necessary, the same treatment can be repeated after a titration period.
- the dose is the same as that of a human per kg, or the above dose is converted, for example, by the volume ratio (for example, average value) of the target animal and the organ (heart, etc.) of the human One dose can be administered.
- an effective amount of the GLP-1/GIP dual agonist, a pharmaceutically acceptable salt thereof, a solvate thereof, or a conjugate thereof may be administered simultaneously, separately, or sequentially with an effective amount of one or more other active ingredients.
- the one or more other active ingredients may be, but are not limited to, one or more other agents for treating inflammatory or autoimmune diseases.
- Another aspect provides the use of the GLP-1/GIP dual agonist, a pharmaceutically acceptable salt thereof, a solvate thereof, or the conjugate for use in the manufacture of a medicament for the prevention or treatment of diabetes.
- the use may be for use in the manufacture of a medicament for preventing or treating diabetic complications.
- the use may be for use in the manufacture of a medicament for the prophylaxis or treatment of metabolic syndrome.
- the GLP-1/GIP dual agonist, a pharmaceutically acceptable salt thereof, a solvate thereof, the conjugate, the pharmaceutical composition, diabetes, diabetic complications, and metabolic syndrome are as described above.
- GLP-1 / GIP dual agonist according to an aspect, or a long-acting conjugate thereof, has an increased half-life and exhibits effects such as blood sugar control, blood sugar reduction, and insulin resistance improvement, so it can be used for prevention or treatment of diabetes, etc. there is.
- 2A shows the results of confirming the blood glucose control effect of the long-acting conjugates of SEQ ID NOs: 20, 36, and 40 in normal mice.
- Figure 3A shows the results of confirming the blood sugar reducing effect of the long-acting conjugate of SEQ ID NO: 20 in the type 2 diabetes model.
- 3B shows the results of confirming the effect of reducing the glycated hemoglobin level in the type 2 diabetes model of the long-acting conjugate of SEQ ID NO: 20.
- Example 1 Preparation of GLP-1/GIP dual agonist having activity on both GLP-1 receptor and GIP receptor
- GLP-1/GIP dual agonists having activity against both the GLP-1 receptor and the GIP receptor were prepared and their sequences are shown in Table 1 below.
- an underlined amino acid means that the underlined amino acids form a ring with each other.
- the amino acid marked with Aib is a non-natural amino acid, aminoisobutyric acid (Aib).
- the amino acid denoted by Nle is norleucine (Nle; 2-aminohexanoic acid), and is an isomer of leucine.
- HP Y means 3-(4-hydroxyphenyl)propanoic acid (3-(4-hydroxyphenyl)propanoic acid, HP; Phloretic acid), and tyrosine (Y) at the N-terminus of the peptide is 3-(4 -Hydroxyphenyl) is replaced with propionic acid to remove the terminal amino group.
- CA H stands for 4-imidazoleacetic acid
- histidine (H) at the N-terminus of the peptide is replaced with 4-imidazoleacetic acid to remove the terminal amino group.
- HA Y means 2-(4-hydroxyphenyl)acetic acid (2-(4-hydroxyphenyl)acetic acid or 4-hydroxyphenylacetic acid, HA), and tyrosine (Y) at the N-terminus of the peptide is 2- It was replaced with (4-hydroxyphenyl)acetic acid to remove the terminal amino group.
- the dual agonist peptide is used as a dual agonist in which the C-terminus is amidated if necessary.
- Example 2 GLP-1/GIP dual agonist in vitro activity measurement
- Example 1 In order to measure the activity of the GLP-1/GIP dual agonist prepared in Example 1, a method for measuring cell activity in vitro using cell lines transformed with GLP-1 receptor and GIP receptor, respectively, was used.
- the cell line was transformed to express human GIP-1 and human GIP receptor genes in CHO (chinese hamster ovary), respectively, and is suitable for measuring the activities of GLP-1 and GIP. Therefore, the activity for each part was measured using each transformed cell line.
- human GLP-1 was serially diluted from 50 nM to 0.000048 nM by 4 times, and the dual agent prepared in Example 1 was diluted from 50 nM to 4 times each Serial dilutions to 0.000048 nM.
- the culture medium was removed from the cultured CHO cells expressing the human GLP-1 receptor, 5 ⁇ l of each serially diluted substance was added to the cells, and then 5 ⁇ l of a buffer containing cAMP antibody was added for 15 minutes. during incubation at room temperature. Then, 10 ⁇ l of a detection mix containing cell lysis buffer was added to lyse the cells, followed by reaction at room temperature for 90 minutes.
- the cell lysate after the reaction was completed was applied to the LANCE cAMP kit (PerkinElmer, USA) to calculate the EC 50 value through the accumulated cAMP, and then compared with each other.
- human GIP was serially diluted from 1 nM to 0.0000095 nM in 4-fold increments, and the dual-agent prepared in Example 1 was continuously diluted from 50 nM to 0.000048 nM in 4-fold increments. was diluted with The culture medium was removed from the cultured CHO cells expressing the human GIP receptor, 5 ⁇ l of each serially diluted substance was added to the cells, and 5 ⁇ l of a buffer containing cAMP antibody was added thereto, followed by room temperature for 15 minutes. cultured in Then, 10 ⁇ l of a detection mix containing cell lysis buffer was added to lyse the cells, followed by reaction at room temperature for 90 minutes. The cell lysate after the reaction was completed was applied to the LANCE cAMP kit (PerkinElmer, USA) to calculate the EC 50 value through the accumulated cAMP, and then compared with each other.
- LANCE cAMP kit PerkinElmer, USA
- Relative titers compared to human GLP-1 and relative titers to human GIP are shown in Table 2 below.
- n/a indicates that the test was performed, but no activity was obtained.
- the novel dual agonist prepared in Example 1 has activity on the GLP-1 receptor and the GIP receptor.
- a long-acting conjugate comprising the dual agent prepared in Example 1 was prepared. Specifically, the dual agents of SEQ ID NOs: 20, 36, and 40 were linked to the immunoglobulin Fc region via PEG, a non-peptidic polymer, respectively.
- the purified mono-pegylated dual agent was reacted with immunoglobulin Fc at a molar ratio of 1:2 to 10, a total protein concentration of 20 to 50 mg/ml, pH 6.0 to 7.0, and 4 to 10° C. for 14 to 18 hours.
- isopropanol and sodium cyanoboro hydride (NaCNBH 3 ) as a reducing agent were added to the reaction solution.
- the reaction solution was purified by using a column of Source 15Q (GE Healthcare Life Science, USA) in which the GLP-1R/GIPR dual agonist was covalently linked by PEG to immunoglobulin Fc.
- the prepared dual agent-PEG-immunoglobulin Fc region conjugate of SEQ ID NO: 20 (hereinafter, 'long-acting conjugate of SEQ ID NO: 20'), the dual agent-PEG-immunoglobulin Fc region conjugate of SEQ ID NO: 36 (hereinafter, 'Long-acting conjugate of SEQ ID NO: 36'), and the dual agonist-PEG-immunoglobulin Fc region conjugate of SEQ ID NO: 40 (hereinafter, 'long-acting conjugate of SEQ ID NO: 40') were analyzed through SE-HPLC and RP-HPLC analysis. It was confirmed that it was prepared with a high purity of 95% or more, and the results of SDS-PAGE analysis are shown in FIG. 1 .
- Each of the cell lines was transformed to express human GLP-1 receptor and human GIP receptor genes in CHO (chinese hamster ovary), respectively, and was the same cell line as that used in Example 2. The activity for each part was measured using each transformed cell line.
- human GLP-1 was serially diluted from 50 nM to 0.000048 nM in 4 folds, and SEQ ID NOs: 20, 36 , and 40 were serially diluted from 12.5 nM to 0.000012 nM in 4-fold increments.
- the culture medium was removed from the cultured CHO cells expressing the human GLP-1 receptor, 5 ⁇ l of each serially diluted substance was added to the cells, and then 5 ⁇ l of a buffer containing cAMP antibody was added for 15 minutes. during incubation at room temperature.
- human GIP was serially diluted from 1 nM to 0.00000095 nM in 4-fold increments, and SEQ ID NOs: 20, 36, and 40
- the long-acting conjugate was serially diluted from 12.5 nM to 0.000012 nM in 4-fold increments.
- the culture medium was removed from the cultured CHO cells expressing the human GIP receptor, 5 ⁇ l of each serially diluted substance was added to the cells, and 5 ⁇ l of a buffer containing cAMP antibody was added thereto, followed by room temperature for 15 minutes.
- Relative titers compared to human GLP-1 and relative titers to human GIP are shown in Table 3 below.
- mice per group were separated into 4 groups of G1, G2, G3 and G4.
- a control group to which none of the above groups was administered (Vehicle), a group to which the long-acting conjugate of SEQ ID NO: 20 was administered (1 nmol/kg), a group to which the long-acting conjugate of SEQ ID NO: 36 was administered (1 nmol/kg), the sequence The long-acting conjugate of No. 40 was administered and divided into groups (1 nmol/kg).
- the test substance was administered subcutaneously, and after 20 hours, they were fasted for 4 hours.
- ipGTT intraperitoneal glucose tolerance test
- 1 g/kg of glucose was intraperitoneally administered, and 1-2 drops of blood obtained by stabbing the caudal vein with a 26 G syringe were used in a blood glucose analyzer (OneTouch Ultra). , LifeScan, Inc., USA) was used to measure mouse blood glucose. Blood glucose was measured before and 15 minutes, 30 minutes, 1 hour, and 2 hours after administration of glucose,
- 2A shows the results of confirming the blood glucose control effect of the long-acting conjugates of SEQ ID NOs: 20, 36, and 40 in normal mice.
- STZ which can destroy pancreatic beta cells
- DIO/STZ rats were prepared by administering a total of 2 times at intervals of 1 week at a dose of 30 mg/kg.
- the manufactured model continued to consume a high-fat diet to maintain diabetes. Diabetes-induced rats were divided into three groups according to blood sugar: G1, G2, and G3.
- a control group to which none of the above groups was administered (Vehicle), a group administered with a low dose of the long-acting conjugate of SEQ ID NO: 20 (3.0 nmol/kg/Q3D), a group administered with a high-dose of the long-acting conjugate of SEQ ID NO: 20 (14.8 nmol/ kg/Q3D).
- Blood glucose and glycated hemoglobin were measured while repeatedly administering the test substance for 5 weeks.
- Blood glucose was measured using a blood glucose analyzer (OneTouch Ultra, LifeScan, Inc., USA) using 1-2 drops of blood obtained by puncturing the caudal vein with a 26 G syringe, and glycated hemoglobin was measured using a diabetes diagnostic device (DCA Vantage, Siemens). AG, Germany).
- HOMA-IR Homeostatic model assessment-Insulin resistance
- Figure 3A shows the results of confirming the blood sugar reducing effect of the long-acting conjugate of SEQ ID NO: 20 in the type 2 diabetes model.
- 3B shows the results of confirming the effect of reducing the glycated hemoglobin level in the type 2 diabetes model of the long-acting conjugate of SEQ ID NO: 20.
- a decrease in blood glucose was confirmed when the long-acting conjugate according to an embodiment was administered to DIO/STD rats for 5 weeks.
- the glycated hemoglobin level was also decreased.
- the blood glucose lowering effect increased in proportion to the administered dose and the glycated hemoglobin decreased in proportion to the administration period and the administered dose, it was confirmed that the dual agent according to an embodiment was directly involved in lowering blood sugar.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
서열번호 | 아미노산 서열 | 고리형성 여부 |
1 | YAibEGTFTSDYSEYMEKEAVREFIAWLVKGGPSSGAPPPSC | 고리형성 |
2 | YAibEGTFTSDYSKYLDEIRAKDFVQWLLDHHPSSGQPPPSC | 고리형성 |
3 | YAibEGTFTSDYSKYLDEIAAKDFVQWLLDHHPSSGQPPPSC | 고리형성 |
4 | YAibEGTFTSDYSKYLDEIRAKDFVQWLLDHHPSSGQPPPC | 고리형성 |
5 | YAibEGTFTSDYSKYLDEKAAKDFVQWLLDHHPSSGQPPPSC | 고리형성 |
6 | YAibEGTFTSDYSKYLDEKRAKDFVQWLLDHHPSSGQPPPSC | 고리형성 |
7 | YAibEGTFTSDYSKYLDERAQKDFVQWLLDHHPSSGQPPPSC | 고리형성 |
8 | YAibEGTFTSDYSKYLDERASKDFVQWLLDHHPSSGQPPPSC | 고리형성 |
9 | YAibEGTFTSDYSRYLDERAAKDFVQWLLDHHPSSGQPPPSK | 고리형성 |
10 | YAibEGTFTSDYSRYLDERAQKDFVQWLLDHHPSSGQPPPSK | 고리형성 |
11 | YAibEGTFTSDYSRYLDERASKDFVQWLLDHHPSSGQPPPSK | 고리형성 |
12 | YAibEGTFTSDYSEYMEKEAVREFIAWLVRGGPSSGAPPPSK | 고리형성 |
13 | YAibEGTFTSDYSEYMEKEAVREFISWLVRGGPSSGAPPPSK | 고리형성 |
14 | HAibEGTFTSDYSKYLDKKRQAibEFVQWLLNGGPSSGAPPPSC | - |
15 | YAibEGTFTSDYSIYLDERACKDFVQWLLDHHPSSGQPPPSYK | 고리형성 |
16 | YAibEGTFTSDYSIAibLDKIAQRAFVQWLIAGGPSSGAPPPSK | - |
17 | YAibEGTFTSDYSIQLDKIAQKAFVQWLIAGGPSSGAPPPSC | - |
18 | YAibEGTFTSDYSIQLDKIAQRAFVQWLIAGGPSSGAPPPSK | - |
19 | YAibEGTFTSDYSIYLDKQAAAibAFVQWLIAGGPSSGAPPPSC | - |
20 | YAibEGTFTSDYSIAibLDKQAAAibAFVQWLIAGGPSSGAPPPSC | - |
21 | YAibEGTFTSDYSIAibLDKIAAKAFVQWLIAGGPSSGAPPPSC | - |
22 | YAibEGTFTSDYSKYLDEKAAKEFVQWLLDQHPSSGQPPPSC | 고리형성 |
23 | YAibEGTFTSDYSKYLDEQAAKEFVQWLLDQHPSSGAPPPSC | 고리형성 |
24 | YAibEGTFTSDYSKYLDEIAQKDFVQWLLDQHPSSGAPPPSC | 고리형성 |
25 | YAibEGTFTSDYSKYLDEEAVKLFVQWLLDQHPSSGAPPPSC | 고리형성 |
26 | YAibEGTFTSDYSIAMDAIAQQDFVNWLLAQKGKKNDWKHNITQC | - |
27 | YAibEGTFTSDYSIAMDAIAQQDFVNWLLAQRGKKSDWKHNITQC | - |
28 | YAibEGTFTSDYSIALEKQAQQDFVNWLLAGGPSSGAPPPSC | - |
29 | YAibEGTFTSDYSIAibLDKQAAAibEFVNWLLAibGGPSSGAPPPSC | - |
30 | YAibEGTFTSDYSIAibLDKQAAAibEFVNWLLAibGHPSSGAPPPSC | - |
31 | HPYAibEGTFTSDYSIAibLDKIAQRAFVQWLIAGGPSSGAPPPSK | - |
32 | HAYAibEGTFTSDYSIAibLDKIAQRAFVQWLIAGGPSSGAPPPSK | - |
33 | CAHYAibEGTFTSDYSIAibLDKIAQRAFVQWLIAGGPSSGAPPPSK | - |
34 | YAibEGTFTSDYSIAibLDKQAARAFVQWLIAGGPSSGAPPPSC | - |
35 | YAibEGTFTSDYSIAibLDKQHAAibAFVQWLIAGGPSSGAPPPSC | - |
36 | YAibEGTFTSDYSIAibLDKQAQQAFVQWLIAGGPSSGAPPPSC | - |
37 | YAibEGTFTSDYSIAibLDKQAQQAibFVQWLIAGGPSSGAPPPSC | - |
38 | YAibEGTFTSDYSIAibLEKQAQQDFVNWLLAGGPSSGAPPPSC | - |
39 | YAibEGTFTSDYSIALEKQAAAibDFVNWLLAGGPSSGAPPPSC | - |
40 | YAibEGTFTSDYSIALEKQAQRDFVNWLLAGGPSSGAPPPSC | - |
41 | HPYAibEGTFTSDYSIAibLDAQAAAibAFVQWLIAGGPSSGAPPPSK | - |
42 | HPYAibEGTFTSDYSIAibLDNleQAAAibAFVQWLIAGGPSSGAPPPSK | - |
43 | HPYAibEGTFISDYSIALEAQAQQDFVNWLLAGGPSSGAPPPSK | - |
44 | HPYAibEGTFISDYSIALENleQAQQDFVNWLLAGGPSSGAPPPSK | - |
서열번호 | 천연형 펩타이드 대비 In vitro 활성(%) | |
vs 인간 GLP-1 | vs 인간 GIP | |
1 | 53.9% | 27.5% |
2 | 3.3% | 28.8% |
3 | 6.8% | 28.7% |
4 | 1.9% | 18.5% |
5 | 20.2% | 48.2% |
6 | 7.4% | 30.9% |
7 | 18.3% | 62.3% |
8 | 35.9% | 29.2% |
9 | 141.0% | n/a |
10 | 108.0% | n/a |
11 | 95.0% | n/a |
12 | 110.0% | n/a |
13 | 116.0% | n/a |
14 | 159.7% | 0.3% |
15 | 97.5% | 64.4% |
16 | 60.0% | 72.3% |
17 | 19.8% | 7.7% |
18 | 43.3% | 15.9% |
19 | 32.8% | 13.9% |
20 | 31.5% | 64.2% |
21 | 19.7% | 23.2% |
22 | 41.1% | 39.6% |
23 | 13.5% | 105.6% |
24 | 7.3% | 83.9% |
25 | 3.2% | 59.4% |
26 | 0.3% | 57.9% |
27 | 0.2% | 55.5% |
28 | 6.7% | 145.8% |
29 | 0.5% | 96.0% |
30 | 1.0% | 63.4% |
31 | 93.3% | 38.3% |
32 | 88.3% | 20.1% |
33 | 3.1% | 14.8% |
34 | 34.2% | 63.4% |
35 | 9.6% | 64.2% |
36 | 79.9% | 217.2% |
37 | 45.2% | 173.9% |
38 | 14.3% | 216.1% |
39 | 15.9% | 143.6% |
40 | 97.7% | 181.1% |
41 | 116.9% | 58.7% |
42 | 69.5% | 35.9% |
43 | 1.2% | 109.4% |
44 | 1.4% | 74.2% |
서열번호 | 천연형 펩타이드 대비 In vitro 활성 (%) | |
vs 인간 GLP-1 | vs 인간 GIP | |
20 | 7.5% | 62.1% |
36 | 3.9% | 26.9% |
40 | 10.1% | 24.7% |
Claims (24)
- 서열번호 1 내지 44로 구성된 군으로부터 선택된 어느 하나의 아미노산 서열을 포함하는 펩타이드.
- 청구항 1에 있어서, 상기 펩타이드는 서열번호 14, 15, 16, 20, 36, 37, 38, 및 40으로 구성된 군으로부터 선택된 어느 하나의 아미노산 서열을 포함하는 것인, 펩타이드.
- 청구항 1에 있어서, 상기 펩타이드는 서열번호 20, 36, 및 40으로 구성된 군으로부터 선택된 어느 하나의 아미노산 서열을 포함하는 것인, 펩타이드.
- 청구항 1에 있어서, GLP-1(Glucagon-like peptide-1) 수용체 및 GIP(glucose-dependent insulinotropic peptide) 수용체에 대해 활성을 갖는 것인, 펩타이드.
- 청구항 1에 있어서, 상기 펩타이드 서열에서 N-말단으로부터 12번 아미노산 및 16번 아미노산, 또는 16번 아미노산 및 20번 아미노산은 서로 고리를 형성하는 것인, 펩타이드.
- 청구항 1에 있어서, 상기 펩타이드는 이의 C-말단이 변형되지 않았거나 아미드화된 것인, 펩타이드.
- 청구항 1 내지 6 중 어느 한 항의 펩타이드를 코딩하는 폴리뉴클레오티드.
- 청구항 7의 폴리뉴클레오티드를 포함하는 벡터.
- 청구항 1 내지 6 중 어느 한 항의 펩타이드와 생체 내 반감기를 증가시키는 생체적합성 물질이 결합된, 결합체.
- 청구항 9에 있어서, 상기 생체적합성 물질은 고분자 중합체, 지방산, 콜레스테롤, 알부민 및 이의 단편, 알부민 결합물질, 특정 아미노산 서열의 반복단위의 중합체, 항체, 항체 단편, FcRn 결합 물질, 생체 내 결합조직, 뉴클레오티드, 피브로넥틴, 트랜스페린(Transferrin), 당류(saccharide), 헤파린, 및 엘라스틴으로 구성된 군으로부터 선택되는 것인, 결합체.
- 청구항 10에 있어서, 상기 고분자 중합체는 폴리에틸렌 글리콜, 폴리프로필렌 글리콜, 에틸렌 글리콜-프로필렌 글리콜 공중합체, 폴리옥시에틸화폴리올, 폴리비닐알콜, 다당류, 폴리비닐에틸에테르, 생분해성 고분자, 지질 중합체, 키틴, 히알루론산, 올리고뉴클레오티드 및 이들의 조합으로 구성된 군으로부터 선택되는 것인, 결합체.
- 청구항 9에 있어서, 상기 생체적합성 물질은 FcRn 결합 물질인 것인, 결합체.
- 청구항 12에 있어서, 상기 FcRn 결합 물질은 면역글로불린 Fc 영역인 것인, 결합체.
- 청구항 13에 있어서, 상기 면역글로불린 Fc 영역은 (a) CH1 도메인, CH2 도메인, CH3 도메인 및 CH4 도메인; (b) CH1 도메인 및 CH2 도메인; (c) CH1 도메인 및 CH3 도메인; (d) CH2 도메인 및 CH3 도메인; (e) CH1 도메인, CH2 도메인, CH3 도메인 및 CH4 도메인 중 1개 또는 2개 이상의 도메인과 면역글로불린 힌지 영역 또는 힌지 영역의 일부와의 조합; 및 (f) 중쇄 불변영역 각 도메인과 경쇄 불변영역의 이량체로 구성된 군으로부터 선택되는 것인, 결합체.
- 청구항 13에 있어서, 상기 면역글로불린 Fc 영역은 비당쇄화된 것인, 결합체.
- 청구항 13에 있어서, 상기 면역글로불린 Fc 영역은 IgG4 Fc 영역인 것인, 결합체.
- 청구항 13에 있어서, 상기 면역글로불린 Fc 영역은 인간 IgG4 유래의 비당쇄화된 Fc 영역인 것인, 결합체.
- 청구항 9에 있어서, 상기 펩타이드는 링커를 통해 생체적합성 물질과 연결되는 것인, 결합체.
- 청구항 18에 있어서, 상기 링커는 펩타이드, 지방산, 당류(saccharide), 고분자 중합체, 저분자 화합물, 뉴클레오티드 및 이들의 조합으로 구성된 군으로부터 선택되는 것인, 결합체.
- 청구항 19에 있어서, 상기 고분자 중합체는 폴리에틸렌 글리콜, 폴리프로필렌 글리콜, 에틸렌 글리콜-프로필렌 글리콜 공중합체, 폴리옥시에틸화폴리올, 폴리비닐알콜, 다당류, 폴리비닐에틸에테르, 생분해성 고분자, 지질 중합체, 키틴, 히알루론산, 올리고뉴클레오티드 및 이들의 조합으로 구성된 군으로부터 선택되는, 결합체.
- 청구항 18에 있어서, 상기 링커는 에틸렌글리콜 반복 단위를 함유하는 것인 것인, 결합체.
- 청구항 21에 있어서, 상기 에틸렌글리콜 반복 단위 부분의 화학식량은 1 내지 100 kDa 범위에 있는 것인, 결합체.
- 청구항 1 내지 5 중 어느 한 항의 펩타이드, 이의 약학적으로 허용가능한 염 또는 이의 용매화물, 또는 청구항 8 내지 22 중 어느 한 항의 결합체를 포함하는, 당뇨병 예방 또는 치료용 약학적 조성물.
- 청구항 23에 있어서, 약학적으로 허용되는 부형제를 더 포함하는 것인, 약학적 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/031,978 US20230382970A1 (en) | 2020-10-16 | 2021-10-18 | Glp-1/gip dual agonist, long-acting conjugate thereof, and pharmaceutical composition comprising same |
JP2023522948A JP2023546090A (ja) | 2020-10-16 | 2021-10-18 | Glp-1/gip二重作用剤、その持続型結合体、及びそれを含む薬学的組成物 |
CN202180070487.9A CN116419765A (zh) | 2020-10-16 | 2021-10-18 | Glp-1/gip双重激动剂、其长效缀合物,以及包括其的药物组合物 |
EP21880632.1A EP4230640A1 (en) | 2020-10-16 | 2021-10-18 | Glp-1/gip dual agonist, long-acting conjugate thereof, and pharmaceutical composition comprising same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200134478 | 2020-10-16 | ||
KR10-2020-0134478 | 2020-10-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022080986A1 true WO2022080986A1 (ko) | 2022-04-21 |
WO2022080986A8 WO2022080986A8 (ko) | 2023-04-27 |
Family
ID=81207482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/014462 WO2022080986A1 (ko) | 2020-10-16 | 2021-10-18 | Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230382970A1 (ko) |
EP (1) | EP4230640A1 (ko) |
JP (1) | JP2023546090A (ko) |
KR (1) | KR20220050820A (ko) |
CN (1) | CN116419765A (ko) |
WO (1) | WO2022080986A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024020388A1 (en) * | 2022-07-20 | 2024-01-25 | Viking Therapeutics, Inc. | Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders |
WO2024133382A1 (en) * | 2022-12-21 | 2024-06-27 | Boehringer Ingelheim International Gmbh | Glp1/gip/npy2 receptor triple agonists |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996032478A1 (en) | 1995-04-14 | 1996-10-17 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US20120288511A1 (en) * | 2009-12-18 | 2012-11-15 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
KR20140020851A (ko) * | 2010-12-22 | 2014-02-19 | 마르카디아 바이오테크, 인코퍼레이트 | Gip 및 glp-1 수용체-활성 글루카곤계 펩타이드를 이용한 대사장애 및 비만의 치료방법 |
KR20160079875A (ko) * | 2013-11-06 | 2016-07-06 | 질랜드 파마 에이/에스 | Gip-glp-1 이원 효능제 화합물 및 방법 |
KR20180090760A (ko) * | 2017-02-03 | 2018-08-13 | 한미약품 주식회사 | 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도 |
-
2021
- 2021-10-18 JP JP2023522948A patent/JP2023546090A/ja active Pending
- 2021-10-18 US US18/031,978 patent/US20230382970A1/en active Pending
- 2021-10-18 CN CN202180070487.9A patent/CN116419765A/zh active Pending
- 2021-10-18 KR KR1020210138602A patent/KR20220050820A/ko unknown
- 2021-10-18 WO PCT/KR2021/014462 patent/WO2022080986A1/ko active Application Filing
- 2021-10-18 EP EP21880632.1A patent/EP4230640A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996032478A1 (en) | 1995-04-14 | 1996-10-17 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US20120288511A1 (en) * | 2009-12-18 | 2012-11-15 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
KR20140020851A (ko) * | 2010-12-22 | 2014-02-19 | 마르카디아 바이오테크, 인코퍼레이트 | Gip 및 glp-1 수용체-활성 글루카곤계 펩타이드를 이용한 대사장애 및 비만의 치료방법 |
KR20160079875A (ko) * | 2013-11-06 | 2016-07-06 | 질랜드 파마 에이/에스 | Gip-glp-1 이원 효능제 화합물 및 방법 |
KR20180090760A (ko) * | 2017-02-03 | 2018-08-13 | 한미약품 주식회사 | 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도 |
Non-Patent Citations (14)
Title |
---|
"Martin J. Bishop", 1994, ACADEMIC PRESS |
ATSCHUL, [S.] [F., J MOLEC BIOL, vol. 215, 1990, pages 403 |
CARILLO, SIAM J APPLIED MATH, vol. 48, 1988, pages 1073 |
DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387 |
GRIBSKOV ET AL., NUCL. ACIDS RES., vol. 14, 1986, pages 6745 |
H.NEURATHR.L.HILL: "Atlas Of Protein Sequence And Structure", 1979, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, pages: 353 - 358 |
NEEDLEMAN, J MOL BIOL., vol. 48, 1970, pages 443 |
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453 |
P. STAHL ET AL.: "Handbook of Pharmaceutical Salts: Properties", 2011, WILEY-VCH |
PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444 |
RICE ET AL.: "EMBOSS: The European Molecular Biology Open Software Suite", TRENDS GENET., vol. 16, 2000, pages 276 - 277, XP004200114, DOI: 10.1016/S0168-9525(00)02024-2 |
S.M. BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, January 1977 (1977-01-01), XP002675560, DOI: 10.1002/jps.2600660104 |
SMITHWATERMAN, ADV. APPL. MATH, vol. 2, 1981, pages 482 |
USUI, RYOTA: "Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity", JOURNAL OF DIABETES INVETIGATION, vol. 10, no. 4, 2019, pages 902 - 905, XP055684372, DOI: 10.1111/jdi.13005 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024020388A1 (en) * | 2022-07-20 | 2024-01-25 | Viking Therapeutics, Inc. | Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders |
WO2024133382A1 (en) * | 2022-12-21 | 2024-06-27 | Boehringer Ingelheim International Gmbh | Glp1/gip/npy2 receptor triple agonists |
Also Published As
Publication number | Publication date |
---|---|
JP2023546090A (ja) | 2023-11-01 |
US20230382970A1 (en) | 2023-11-30 |
WO2022080986A8 (ko) | 2023-04-27 |
CN116419765A (zh) | 2023-07-11 |
EP4230640A1 (en) | 2023-08-23 |
KR20220050820A (ko) | 2022-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017116205A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 | |
AU2016287209B2 (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
WO2017052321A1 (ko) | 다수의 생리활성 폴리펩타이드 및 면역글로불린 Fc 영역을 포함하는, 단백질 결합체 | |
WO2012173422A1 (en) | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof | |
WO2018004283A2 (ko) | 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도 | |
WO2015108398A1 (ko) | 지속형 인슐린 및 그 용도 | |
WO2022080986A1 (ko) | Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 | |
WO2014073845A1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
WO2015152618A1 (ko) | 면역글로불린 fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법 | |
WO2019066586A1 (ko) | 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 | |
WO2017116207A1 (ko) | Fgf21 아날로그, fgf21 결합체, 및 이의 용도 | |
WO2020130749A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물 | |
WO2018174668A2 (ko) | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 | |
WO2019066570A1 (ko) | 지속형 단쇄 인슐린 아날로그 및 이의 결합체 | |
WO2022015082A1 (ko) | 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도 | |
WO2021066600A1 (ko) | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 | |
WO2022080987A1 (ko) | 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 혈관염 예방 또는 치료용 약학적 조성물 | |
WO2023106845A1 (ko) | 신규한 아디포넥틴 아날로그 및 결합체 | |
WO2021215801A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법 | |
WO2022015115A1 (ko) | 3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도 | |
WO2021182928A1 (ko) | 신규 이중 특이성 단백질 및 그의 용도 | |
WO2020263063A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도 | |
WO2022080989A1 (ko) | 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2020214013A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도 | |
WO2021235907A1 (ko) | 글루카곤 유도체의 지속형 결합체의 액상 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21880632 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023522948 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18031978 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021880632 Country of ref document: EP Effective date: 20230516 |